Please try another search
For the six months ended 30 June 2020, Principia Biopharma Inc revenues increased 42% to $50M. Net loss increased from $6.6M to $21.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase of 64% to $51.4M (expense), General and administrative - Balancing increase of 64% to $11.5M (expense).
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 50 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | 9.88 | -34.11 | -26.61 | -23.33 |
Net Income | 10.81 | -32.5 | -24.92 | -22.3 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 385.95 | 362.77 | 382.74 | 174.09 |
Total Liabilities | 34.51 | 31.33 | 23.76 | 21.41 |
Total Equity | 351.44 | 331.45 | 358.98 | 152.68 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -54.43 | -27.47 | -42.55 | -20.87 |
Cash From Investing Activities | 182.88 | 46.84 | -182.62 | 13.62 |
Cash From Financing Activities | 2.49 | 0.52 | 230.13 | 2.09 |
Net Change in Cash | 130.95 | 19.89 | 4.97 | -5.16 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review